Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

161. Systematic review with meta analysis: Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes

Systematic review with meta analysis: Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you (...) Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes Article Text Therapeutics/Prevention Systematic review with meta analysis Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes David W Johnson Statistics from Altmetric.com Commentary on: Cody JD , Hodson EM . Recombinant

2016 Evidence-Based Medicine

162. ERBP Guideline on Management of Older Patients with Chronic Kidney Disease Full Text available with Trip Pro

assessment 95% CI 95% Confidence Interval AKI Acute kidney injury CKD Chronic kidney disease CKD-EPI Chronic Kidney Disease Epidemiology Collaboration CM Conservative management eGFR Estimated glomerular filtration rate ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP European Renal Best Practice ESKD End-stage kidney disease HD Hemodialysis HR Hazard ratio KFRE Kidney Failure Risk Equation MD Mean Difference MDRD Modification of Diet in Renal Disease OR Odds Ratio (...) PD Peritoneal dialysis QoL Quality of life RCT Randomized controlled trial REIN Renal Epidemiology and Information Network RR Relative Risk RRT Renal replacement therapy SGA Subjective global assessment 95% CI 95% Confidence Interval AKI Acute kidney injury CKD Chronic kidney disease CKD-EPI Chronic Kidney Disease Epidemiology Collaboration CM Conservative management eGFR Estimated glomerular filtration rate ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP

2016 European Renal Best Practice

163. What Is the Significance of Elevated Troponin in Patients With Suspected Acute Coronary Syndrome and Chronic Kidney Disease?

. Cardiac troponin I and creatine kinase MB isoenzyme in patients with chronic renal failure. Nefrologia. 2012;32:809-818. 2. Kanderian AS, Francis GS. Cardiac troponins and chronic kidney disease. Kidney Int. 2006;69:1112-1114. 3. Michos ED, Wilson LM, Yeh HC, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome. Ann Intern Med.2014;161: 491-501. 4. Khan NA, Hemmelgarn BR, Tonelli M, et al. Prognostic value of troponin T and I (...) among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation. 2005;112:3088-3096. 5. Amsterdam EZ, Wenger NK, Peterson ED, et al. 2014 AHA/ACC guideline for the management of patients with non-ST- elevation acute coronary syndromes.JAm Coll Cardiol. 2014;64:e139-228. 6. Acharji S, Baber U, Mehran R, et al. Prognostic signi?cance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney Systematic Review Snapshot 108 Annals of Emergency

2016 Annals of Emergency Medicine Systematic Review Snapshots

164. Racial disparities in chronic kidney diseases in the United States; a pressing public health challenge with social, behavioral and medical causes Full Text available with Trip Pro

on Ethnicity, Culture and Health, School of Public Health, University of Michigan, Ann Arbor, MI, USA. eng R01 AG018418 AG NIA NIH HHS United States Editorial 2015 12 12 Iran J Nephropharmacol 101679372 2345-4202 Chronic kidney disease End stage renal disease Health disparities Socio-economics 2015 10 07 2015 12 05 2017 2 16 6 0 2015 12 12 0 0 2015 12 12 0 1 epublish 28197489 PMC5297505 Am J Mens Health. 2013 Jul;7(4 Suppl):58S-67S 23609347 J Diabetes Complications. 2003 Jan-Feb;17(1):39-58 12505756 Clin J (...) Racial disparities in chronic kidney diseases in the United States; a pressing public health challenge with social, behavioral and medical causes 28197489 2018 11 13 2345-4202 5 1 2016 Journal of nephropharmacology J Nephropharmacol Racial disparities in chronic kidney diseases in the United States; a pressing public health challenge with social, behavioral and medical causes. 4-6 Assari Shervin S Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA ; Center for Research

2015 Journal of nephropharmacology

165. Endothelin 1 gene is not a major modifier of chronic kidney disease advancement among the autosomal dominant polycystic kidney disease patients Full Text available with Trip Pro

Endothelin 1 gene is not a major modifier of chronic kidney disease advancement among the autosomal dominant polycystic kidney disease patients Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the presence of numerous cysts in the kidney and manifest with various renal and extra-renal complications leading to ESRD. Endothelin may contribute to various renal and extra-renal manifestations pointing to genetic and environmental modifying factors that alter (...) the risk of developing chronic kidney disease (CKD) in ADPKD. In the present study we investigated six genes coding for endothelin 1 ( EDN1 ) tagging-single nucleotide polymorphisms (tag-SNPs) to unravel the EDN1 gene modifier effect for renal disease progression in ADPKD. Materials and Methods: The tag-SNPs were genotyped using FRET-based KASPar method in 108 ADPKD patients and 119 healthy subjects. Cochran-Armitage trend test was used to determine the association between ADPKD and EDN1 tag-SNPs

2015 Journal of nephropharmacology

166. Sucroferric oxyhydroxide (Velphoro) - for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD)

Sucroferric oxyhydroxide (Velphoro) - for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD) Sonidegib (Odomzo ® ) capsule Novartis Pharmaceuticals UK Ltd November 2015 Advice context: The All Wales Medicines Strategy Group (AWMSG) takes into account the National Institute for Health and Care Excellence (NICE) future work programme when considering whether a product will be appraised. To avoid duplication

2015 All Wales Medicines Strategy Group

167. A suPAR Biomarker for Chronic Kidney Disease. (Abstract)

A suPAR Biomarker for Chronic Kidney Disease. 26539740 2015 11 23 2018 12 02 1533-4406 373 20 2015 Nov 12 The New England journal of medicine N. Engl. J. Med. A suPAR Biomarker for Chronic Kidney Disease. 1971-2 10.1056/NEJMe1512997 Skorecki Karl L KL From the Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Rambam Health Care Campus, Haifa, Israel (K.L.S.); and the Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, NC (...) (B.I.F.). Freedman Barry I BI eng Editorial Comment 2015 11 05 United States N Engl J Med 0255562 0028-4793 0 Receptors, Urokinase Plasminogen Activator AIM IM N Engl J Med. 2015 Nov 12;373(20):1916-25 26539835 Female Glomerular Filtration Rate Humans Kidney physiology Male Receptors, Urokinase Plasminogen Activator blood Renal Insufficiency, Chronic diagnosis 2015 11 6 6 0 2015 11 6 6 0 2015 12 15 6 0 ppublish 26539740 10.1056/NEJMe1512997

2015 NEJM

168. Soluble Urokinase Receptor and Chronic Kidney Disease. Full Text available with Trip Pro

Soluble Urokinase Receptor and Chronic Kidney Disease. Relatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) have been associated with focal segmental glomerulosclerosis and poor clinical outcomes in patients with various conditions. It is unknown whether elevated suPAR levels in patients with normal kidney function are associated with future decline in the estimated glomerular filtration rate (eGFR) and with incident chronic kidney disease.We measured (...) plasma suPAR levels in 3683 persons enrolled in the Emory Cardiovascular Biobank (mean age, 63 years; 65% men; median suPAR level, 3040 pg per milliliter) and determined renal function at enrollment and at subsequent visits in 2292 persons. The relationship between suPAR levels and the eGFR at baseline, the change in the eGFR over time, and the development of chronic kidney disease (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were analyzed with the use of linear mixed models and Cox

2015 NEJM

169. The double challenge of resistant hypertension and chronic kidney disease. (Abstract)

chronic kidney disease is associated with an impaired prognosis in patients with resistant hypertension. Recommended low-salt diet and triple antihypertensive drug regimens that include a diuretic, should be complemented by the sequential addition of other antihypertensive drugs. New therapeutic innovations for resistant hypertension, such as renal denervation and carotid barostimulation, are under investigation especially in patients with advanced chronic kidney disease. We discuss resistant (...) The double challenge of resistant hypertension and chronic kidney disease. Resistant hypertension is defined as blood pressure above goal despite adherence to a combination of at least three optimally dosed antihypertensive medications, one of which is a diuretic. Chronic kidney disease is the most frequent of several patient factors or comorbidities associated with resistant hypertension. The prevalence of resistant hypertension is increased in patients with chronic kidney disease, while

2015 Lancet

170. Evaluation of Rhubarb Supplementation in Stages 3 and 4 of Chronic Kidney Disease: A Randomized Clinical Trial. Full Text available with Trip Pro

Evaluation of Rhubarb Supplementation in Stages 3 and 4 of Chronic Kidney Disease: A Randomized Clinical Trial. Objective. To evaluate the efficacy and safety of Rhubarb supplementation in patients of chronic kidney disease. Material and Methods. This study was a prospective comparative study conducted in patients of chronic kidney disease (stages 3 & 4) attending Renal Clinic of Department of Medicine, JN Medical College & Hospital, AMU, Aligarh. Patients were randomly divided into two (...) management in stage 3 and stage 4 patients of chronic kidney disease.

2015 International journal of chronic diseases Controlled trial quality: uncertain

171. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. (Abstract)

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronic kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronic kidney disease have few treatment options. This study assesses an all-oral, ribavirin-free regimen (...) in patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease.In this phase 3 randomised study of safety and observational study of efficacy, patients with HCV genotype 1 infection and chronic kidney disease (stage 4-5 with or without haemodialysis dependence) were randomly assigned to receive grazoprevir (100 mg, NS3/4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment group) or placebo (deferred treatment group) once daily for 12 weeks. Randomisation was done

2015 Lancet Controlled trial quality: predicted high

172. A Positive Association Between Periodontal Disease and Chronic Kidney Disease is Evident, But Periodontal Treatment Effects Unknown

A Positive Association Between Periodontal Disease and Chronic Kidney Disease is Evident, But Periodontal Treatment Effects Unknown UTCAT2938, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title A Positive Association Between Periodontal Disease and Chronic Kidney Disease is Evident, But Periodontal Treatment Effects Unknown Clinical Question In patients with chronic kidney disease, does periodontal treatment improve (...) kidney function (estimated glomerular filtration rate (eGFR))? Clinical Bottom Line Periodontal disease and chronic kidney disease share similar risk factors (smoking, impaired wound healing, diabetes mellitus, malnutrition, and poor oral hygiene) and a positive association between the two diseases has been shown. Intervention studies offer limited and inconsistent evidence for improvement following periodontal treatment in patients with CKD and periodontitis. No adverse outcomes were seen

2015 UTHSCSA Dental School CAT Library

173. Guidelines for the Management of Chronic Kidney Disease (CKD)

with a hospital referral 21 Patient involvement in CKD 21 Appendices Appendix 1 - Where can I get more information? 22 Appendix 2 - Contact Details 23 Appendix 3 - Management of chronic kidney disease: summary table 24 Appendix 4 - Abbreviations 25 Appendix 5 - Membership of GDG 26 3 Introduction Chronic kidney disease (CKD) is common, usually unrecognised and often exists in association with other conditions such as diabetes and cardiovascular disease. CKD is a general term covering a number of primary (...) risk of cardiovascular events, acute kidney injury, falls, frailty and mortality. Table 1: Prevalence of Chronic Kidney Disease Stage Description eGFR (mL/min/1.73m 2 ) Population Prevalence 1 CKD with normal GFR + other kidney damage >90 3.3% 2 Mild CKD and other kidney damage 60-89 3.0% 3a 3b Mild to Moderate CKD Moderate to Severe CKD 45-59 30-44 4.3% 4 Severe CKD 15-29 0.2% 5 Established renal failure 30mg/mmol (macro-albuminuria often dipstick proteinuria) ? GFR in healthy young adults

2015 Regulation and Quality Improvement Authority

174. Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions Full Text available with Trip Pro

equation to estimate GFR is superior for predicting adverse outcomes after PCI and to examine how equation selection would impact drug-dosing recommendations.Estimated GFR (eGFR) was calculated with the Cockcroft-Gault, Modification of Diet in Renal Disease Study (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations for 128,805 patients undergoing PCI in the state of Michigan. Agreement between patient pre-PCI eGFR estimates and resultant CKD stage classifications (...) Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions Multiple equations exist to estimate glomerular filtration rate (GFR); however, there is no consensus on which is superior for risk classification in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI).The goals of this study were to identify which

2015 EvidenceUpdates

175. Chronic kidney disease. Full Text available with Trip Pro

Chronic kidney disease. This issue provides a clinical overview of chronic kidney disease, focusing on prevention, diagnosis, treatment, and patient information. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including ACP Smart Medicine and MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic from these primary sources in collaboration

2015 Annals of Internal Medicine

176. Erythropoiesis Stimulating Agents in Chronic Kidney Disease

. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Erythropoiesis Stimulating Agents in Chronic Kidney Disease (...) of vascular access thrombosis and stroke. No impacts of higher Hb targets were observed on end-stage renal disease or all-cause mortality. 2 The identified randomized controlled trial 3 examined the effects of maintaining high Hb on renal function in patients with CKD who were not on dialysis. Patients were randomized to either a Erythropoiesis Stimulating Agents in Chronic Kidney Disease 3 high Hb group (Hb equal to 11.0 g/dL through 13.0 g/dL) receiving darbepoetin alfa or a low Hb group (Hb equal

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

177. Dialysis in Stage 5 Chronic Kidney Disease

, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Dialysis in Stage 5 Chronic Kidney Disease: Clinical Effectiveness and Guidelines DATE (...) estimated GFRs was statistically significantly associated with increased risk of mortality; however, significant study heterogeneity was also noted. Dialysis in Stage 5 Chronic Kidney Disease 3 REFERENCES SUMMARIZED Health Technology Assessments No literature identified Systematic Reviews and Meta-analyses 1. O'Connor NR, Kumar P. Conservative management of end-stage renal disease without dialysis: a systematic review. J Palliat Med [Internet]. 2012 Feb [cited 2015 Mar 13];15(2):228-35. Available from

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

178. Non-Steroidal Anti-Inflammatory Drugs in Patients with Hypertension, Chronic Kidney Disease, or Heart Failure

Non-Steroidal Anti-Inflammatory Drugs in Patients with Hypertension, Chronic Kidney Disease, or Heart Failure Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time (...) -Inflammatory Drugs in Patients with Hypertension, Chronic Kidney Disease, or Heart Failure: Benefits, Harms, and Guidelines DATE: 10 March 2015 RESEARCH QUESTIONS 1. What are the clinical benefits and harms of using non-steroidal anti-inflammatory drugs (NSAIDS) in patients with hypertension, chronic kidney disease, or heart failure? 2. What are the evidence-based guidelines for using NSAIDS in patients with hypertension, chronic kidney disease, or heart failure? KEY FINDINGS One systematic review, one

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

179. Cohort study: Stricter systolic blood pressure control is associated with higher all-cause mortality in patients with chronic kidney disease Full Text available with Trip Pro

Cohort study: Stricter systolic blood pressure control is associated with higher all-cause mortality in patients with chronic kidney disease Stricter systolic blood pressure control is associated with higher all-cause mortality in patients with chronic kidney disease | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) disease Article Text Prognosis Cohort study Stricter systolic blood pressure control is associated with higher all-cause mortality in patients with chronic kidney disease Nisha Bansal Statistics from Altmetric.com Commentary on : Kovesdy CP , Lu JL , Molnar MZ , et al . Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease . Context Hypertension is a major cause of mortality. Previous studies have identified a J-shaped association between

2015 Evidence-Based Medicine

180. Qualitative?other: People with coexisting diabetes, chronic kidney disease and hypertension report the psychosocial effects of being prescribed multiple medications Full Text available with Trip Pro

Qualitative?other: People with coexisting diabetes, chronic kidney disease and hypertension report the psychosocial effects of being prescribed multiple medications People with coexisting diabetes, chronic kidney disease and hypertension report the psychosocial effects of being prescribed multiple medications | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn (...) more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here People with coexisting diabetes, chronic kidney disease and hypertension report

2015 Evidence-Based Nursing